JPRN-UMIN000008576
Completed
未知
To investigate the efficacy and safety of lenalidomide and dexamethasone for elderly or frail patients with relapsed/refractory multiple myeloma - Iwate Study MM2012
Iwate Myeloma treatment Study Group0 sites53 target enrollmentAugust 1, 2012
ConditionsMultiple Myeloma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Multiple Myeloma
- Sponsor
- Iwate Myeloma treatment Study Group
- Enrollment
- 53
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. History of hypersensitivity to lenalidomide. 2\. Non\-secretory MM and plasma cell leukemia. 3\. Patients HIV\-positive, HBsAg\-positive, HCV\-positive. 4\. Severe hepatic dysfunction, severe renal failure, severe cardiac dysfunction, severe pulmonary dysfunction, uncontrolled hypertension, and uncontrolled infection. 5\. Patients with psychiatric disorders. 6\. Pregnant women, pre\-menopausal women and lactating women. 7\. Patients with a history of active malignancy. 8\. Those who are considered as inappropriate register by attending physicians.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002POEMS SYNDROMEMedDRA version: 9.1Level: SOCClassification code 10029205EUCTR2008-003202-33-ITISTITUTO CLINICO HUMANITAS
Recruiting
Phase 2
A feasibility study to evaluate the utility of a drug (lenalidomide) for preventing recurence in patients with Primary central nervous system lymphoma.This study will use a drug called lenalidomide for 2 years after completion of standard treatment with aim of preventing recurences.CTRI/2019/04/018546Tata Memorial Center
Active, not recruiting
Phase 1
Phase II study evaluating the efficacy of Lenalidomide in association with Rituximab in refractory or relapse of primary central nervous system lymphomaPrimary central nervous system or Intra ocular lymphoma in relapse or refractory to previous treatmentMedDRA version: 14.1Level: LLTClassification code 10051811Term: Cerebral lymphomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2012-003786-17-FRINSTITUT CURIE45
Completed
Phase 4
The study to evaluate the efficacy and safety of linear high intensity focus ultrasound for enlarged pores in Thailand, Pilot studyHealthy human volunteersHigh intensity focused ultrasoundFaceSkinTCTR20220701006Dermatologic Surgery, Dermatology department, Siriraj hospital, Thailand30
Completed
Phase 4
The study to evaluate the efficacy and safety of linear high intensity focus ultrasound for lower face sagging in Thailand, A pilot studyHealthy human volunteersHigh intensity focused ultrasoundFaceSkinTCTR20220629011Dermatologic Surgery, Dermatology department, Siriraj hospital, Thailand30